Year All20242023202220212020201920182017201620152014 Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial May 14, 2020 Read More Abivax postpones the publication of the yearly universal registration document (“URD”) April 29, 2020 Read More Abivax 2019 Financial Results and Operations Update March 16, 2020 Read More Abivax 2020 Financial Communication Calendar March 11, 2020 Read More Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma February 26, 2020 Read More Abivax to Host Satellite Symposium at 15th Congress of the European Crohn’s and Colitis Organization (ECCO) in Vienna January 28, 2020 Read More Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis January 20, 2020 Read More Abivax: 2020 Financial Communication Calendar January 20, 2020 Read More Abivax Receives French Regulatory Authority (ANSM) Approval to Include French Study Sites in its Phase 2b Ulcerative Colitis Clinical Trial and Provides a Progress Update of the ABX464 Clinical Development Plan in other Inflammatory Diseases November 21, 2019 Read More ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference October 21, 2019 Read More
Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial May 14, 2020 Read More
Abivax postpones the publication of the yearly universal registration document (“URD”) April 29, 2020 Read More
Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma February 26, 2020 Read More
Abivax to Host Satellite Symposium at 15th Congress of the European Crohn’s and Colitis Organization (ECCO) in Vienna January 28, 2020 Read More
Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis January 20, 2020 Read More
Abivax Receives French Regulatory Authority (ANSM) Approval to Include French Study Sites in its Phase 2b Ulcerative Colitis Clinical Trial and Provides a Progress Update of the ABX464 Clinical Development Plan in other Inflammatory Diseases November 21, 2019 Read More
ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference October 21, 2019 Read More
